Fig. 3. Edaravone reduces pulmonary injury in HPH mice.
(A) H&E staining was used to reveal the pathological changes of lung tissue and the remodeling of pulmonary vessels (×200); terminal deoxynucleotidyl transferase dUTP nick end labeling was used to reveal pulmonary cell apoptosis (×200). (B, C) RVSP, mPAP, and RV / (LV + S) were measured. Enzyme-linked immunosorbent assay was performed to detect the expression of TNF-α (D) and IL-6 (E) in serum and lung tissue. (F) The expression of MAD and SOD was measured. (G) Immunohistochemistry was used to reveal the expression of α-SMA in pulmonary arterioles (×200). The data were expressed as mean ± SD. n = 10. HPH, hypoxic pulmonary hypertension; WT, wall thickness; RVSP, right ventricular systolic pressure; mPAP, mean pulmonary artery pressure; RV, right ventricle; LV, left ventricle; S, septum; TNF, tumor necrosis factor; IL, interleukin; MAD, malondialdehyde; SOD, superoxide dismutase; α-SMA, α-smooth muscle actin. *p < 0.05, **p < 0.01, and ***p < 0.001, compared with the control group. #p < 0.05 and ##p < 0.01, compared with the HPH group.
© Korean J Physiol Pharmacol
